BioSpace News Archive

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the second quarter ended June 30, 2022.

Eyenovia, Inc., a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology, announced its financial and operating results for the second quarter ended June 30, 2022.

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2022 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2022 with the United States Securities and Exchange Commission (SEC).

Immuneering Corporation, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, reported financial results for the second quarter ended June 30, 2022 and provided recent business highlights.

Societal CDMO, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, reported financial results for the second quarter and six months ended June 30, 2022.

Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced financial results for the three months and nine months ended June 30, 2022.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced second quarter 2022 financial results and provided a business update.

Gritstone bio, Inc., a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, announced the appointment of Lawrence “Larry” Corey, M.D., to its Board of Directors.

HilleVax, Inc. reported financial results for the quarter ended June 30, 2022, highlighted recent program progress, and outlined key upcoming milestones for HIL-214, the company’s investigational virus-like particle based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis.

Adamis Pharmaceuticals Corporation reported financial results for the second quarter of 2022 and provided an update on recent corporate developments.